Immuno-oncology agent IPI-549 is a modulator of P-glycoprotein (P-gp, MDR1, ABCB1)-mediated multidrug resistance (MDR) in cancer: In vitro and in vivo.
Sign Up to like & getrecommendations! Published in 2019 at "Cancer letters"
DOI: 10.1016/j.canlet.2018.10.020
Abstract: Phosphoinositide 3-kinase gamma isoform (PI3Kγ) plays a critical role in myeloid-derived cells of the immunosuppressive tumor microenvironment. IPI-549, a recently discovered small molecule selective PI3Kγ inhibitor, is currently under immuno-oncology clinical trials in combination with… read more here.
Keywords: immuno oncology; mdr; sw620 ad300; ipi 549 ... See more keywords
Cryptotanshinone induces ROS-dependent autophagy in multidrug-resistant colon cancer cells.
Sign Up to like & getrecommendations! Published in 2017 at "Chemico-biological interactions"
DOI: 10.1016/j.cbi.2017.06.003
Abstract: The development of novel chemotherapeutic agents is highly desired for colon cancer treatment, in particular for the multidrug-resistant cancer types. Cryptotanshinone (CTS), an active quinoid diterpene isolated from Salvia miltiorrhiza Bunge, was previously reported to… read more here.
Keywords: sw620 ad300; colon; colon cancer; multidrug resistant ... See more keywords